Middle East and Africa Anti-Fungal Agents Market Research Report Information, by Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis and Others), Drug Class (Azoles, Pyrimidines, Echinocandins, Polyenes, Allylamines and Others) and Route of Administration (Oral, Local and Others) - Forecast to 2032

Antifungal Agents Market Overview

The antifungal agents market will reach USD 6.88 billion and a CAGR of 5.5% in the forecast period 2023-2032.

The antifungal medication, called antimycotic medication, is a pharmaceutical fungicide for the treatment and prevention of mycoses like ringworm, candidiasis, cryptococcal meningitis, and others. There are antifungal drugs available to combat fungal infections. Antifungal drugs are diverse. They are given orally, with topical treatment, or via IV.

Antifungal agents are used for fungal infection treatment. According to the global action fund for fungal infection, over 300 billion suffer from a serious fungal infection every year.

The increased growth of the global antifungal market is due to the rise in cases of fungal and nosocomial infections. Additionally, the surge in initiatives by public and private organizations for awareness about fungal infections will expand the antifungal drugs market. Moreover, the growth of fungal infections such as aspergillosis and candidiasis is the key factor that propels the growth of the antifungal market.

The market drivers include rising concern of fungal infections, awareness, the rise of immunity deficient populations like geriatrics, exposure to infectious agents, and environmental factors such as pollution, particulates, and agriculture residues. The growth of fungal infection due to broad-spectrum antibiotics is another cause behind the growth of the antifungal agents market.

September 2023: BDR Pharmaceutical, a pharmaceutical business, has just introduced Zisavel capsules for the treatment of invasive aspergillosis and mucormycosis, which are both fungal illnesses. This generic drug, belonging to the category of azole antifungals, is available at a cost that is just one-third of the price of the present therapy offered by the original manufacturers. BDR Pharmaceuticals' objective is to ensure that the cost of treating invasive fungal illnesses with isavuconazole is comparable to that of voriconazole and posaconazole, which are both newer antifungal medications. The objective of this project is to expand the availability of these essential medications, guaranteeing their accessibility to patients who now face financial difficulties in obtaining them. The prevalence of fungal diseases differs significantly depending on geographical location, kind of infection, disease severity, and other socioeconomic factors. Isavuconazole will have a significant impact on managing the infection and improving overall life expectancy.

January 2024: Fresenius Kabi has recently launched Posaconazole Injection, a generic alternative to Noxafil®, intended for the treatment or prevention of severe fungal infections in individuals, including adults and children, who are at a higher risk of contracting such infections due to a compromised immune system. Fresenius Kabi has added Posaconazole Injection to its portfolio of over 30 anti-infective compounds, which is now available in the United States. Posaconazole Injection is a medication used to treat invasive aspergillosis, a severe fungal infection, in adults and teens aged 13 and above. It is available in a vial containing 300 mg per 16.7 mL. Additionally, it is employed as a prophylactic measure against invasive aspergillus and candida infections in severely immunocompromised patients, encompassing both adults and children patients aged 2 or above.

Middle East and Africa Anti-fungal Agents Market, by Product Type, 2015 (%):

Study Objectives Middle East and Africa Anti-Fungal Agents Market:

• To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Middle East and Africa anti-fungal agents market


• To provide insights about factors affecting the market growth


• To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments for Middle East and Africa anti-fungal agents market


• To provide country level analysis of the market with respect to the current market size and future prospective


• To provide country level analysis of the market for segments by product type, by construction material, by end users and other sub segments.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Intended Audience

• Anti-fungal agents Manufacturers


• Anti-fungal agents Suppliers


• Private Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Government Research Laboratories


• Contract Manufacturing Organizations

Key Players for Middle East and Africa Anti-fungal Agents Market

Some of the key players in this market are: 

• Novartis AG


• Pfizer, Inc.


• Sanofi-Aventis


• Merck & Co., Inc.


• Enzon Pharmaceuticals, Inc


• Bayer AG


• Astellas Pharma, Inc.


• GlaxoSmithKline plc


• Abbott


• Sigma-Aldrich

Middle East and Africa Anti-fungal Agents Market Segmentation

Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.

Recent Development

In May 2022

SCYNEXIS, Inc., a global biotechnology company with pioneering innovative medicines to overcome and prevent drug-resistant infections, to present data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists meeting being held in San Diego on May 6-8, 2022.

In May 2022

FDA Approves Vivjoa or Chronic Yeast Infections. It is the first FDA-approved trusted Source antifungal medication to treat yeast infection.

The FDA has approved the drug based on phase three clinical trials with 875 patients. Participants in one group received Vivjoa for an initial infection and then for 50 weeks as a maintenance medication. The second group received fluconazole, a traditional treatment for yeast infections, and a placebo for 50 weeks.

Regional Analysis of Middle East and Africa Anti-fungal Agents Market

UAE is the largest market for anti-fungal agents in entire Middle East and Africa anti-fungal Market closely followed by Egypt. The rest of Africa market is however the fastest growing with a huge unmet medical needs and peculiar climatic conditions that support growth of fungal infections.

The report for Middle East and Africa Anti-fungal agents Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.